FRI-502-Factors impacting survival in a large cohort of patients with unresectable hepatocellular carcinoma treated with Y-90 resin microspheres at a single centre

2019 ◽  
Vol 70 (1) ◽  
pp. e620-e621
Author(s):  
Rucha Shah ◽  
Sarah Sheikh ◽  
Jimmy Shah ◽  
Alejandro Mejia ◽  
Islam Shahin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Large Cohort ◽  
Single Centre ◽  
Unresectable Hepatocellular Carcinoma ◽  
Resin Microspheres

scholarly journals Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma

2020 ◽  
Author(s):  
Noemi Muszbek ◽  
Edit Remak ◽  
Rachel Evans ◽  
Victoria K Brennan ◽  
Fabien Colaone ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Cost Utility ◽  
Phase Iii ◽  
Selective Internal Radiation Therapy ◽  
Internal Radiation ◽  
Unresectable Hepatocellular Carcinoma ◽  
Selective Internal Radiation ◽  
Internal Radiation Therapy ◽  
Resin Microspheres

Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Materials & methods: A lifetime partitioned survival model was developed for patients with low tumor burden (≤25%) and good liver function (albumin–bilirubin grade 1). Efficacy, safety and quality of life data were from a European Phase III randomized controlled trial and published studies. Resource use was from registries and clinical surveys. Results: Discounted quality-adjusted life-years were 1.982 and 1.381, and discounted total costs were £29,143 and 30,927, for SIRT and sorafenib, respectively. Conclusion: SIRT has the potential to be a dominant (more efficacious/less costly) or cost-effective alternative to sorafenib in patients with unresectable hepatocellular carcinoma.

Sign in / Sign up

Export Citation Format

Share Document